Effects of sustained release bovine somatotropin (sometribove) on animal health in commercial dairy herds.

The health of dairy cows given bovine somatotropin (bST) for one lactation was evaluated in 28 commercial herds located in four regions of the United States. At least six herds were in a region and at least one herd/region contained fewer than 60 cows. Cows (n = 1213) were assigned randomly to control or bST groups and were treated beginning in wk 9 to 10 of lactation and every 14 d until dry-off or d 400 of lactation.

Recombinant bovine somatotropin (rbST) increases size and proportion of fast-glycolytic muscle fibers in semitendinosus muscle of creep-fed steers.

The objective of this study was to determine the effect of recombinant bovine somatotropin (rbST) on muscle fiber histology and histochemistry in creep-fed beef steers. Crossbred steer calves were assigned to one of two treatment groups: control (sham-injected; n = 12) or rbST-injected (0.09 mg x kg(-1) x d(-1); n = 12).

The effects of long-term administration of recombinant bovine somatotropin (Posilac) and Synovex on performance, plasma hormone and amino acid concentration, and muscle and subcutaneous fat fatty acid composition in Holstein-Friesian bull calves.

The effect of recombinant somatotropin (rbST), Synovex (Syn), and their combination (rbST+Syn) on intact male calves was examined in an experiment that lasted an average of 238 d. Holstein-Friesian bull calves were allotted to one of four subtreatments (n = 14/treatment) in a factorial arrangement. There were two levels of rbST (0; rbST) and two levels of the estrogenic growth promoter Synovex (0; Syn).

Recombinant bovine somatotropin (rbST) administration to creep-fed beef calves increases muscle mass but does not affect satellite cell number or concentration of myosin light chain-1f mRNA.

Our objective in this study was to determine the effect of recombinant bovine somatotropin (rbST) on indices of muscle development in creep-fed beef calves. Crossbred steer calves were assigned to one of two treatment groups: control (sham-injected; n = 12) or rbST-treated (.09 mg x kg(-1) x d(-1); n = 12).

Growth performance, endocrine, and metabolite responses of finishing hogs to porcine prolactin.

Prolactin, a member of the somatotropin-prolactin-placental lactogen gene family, increases feed intake and rate of weight gain in several species. To determine whether prolactin affects growth performance and carcass composition in swine, recombinant porcine prolactin (rpPRL) was administered to finishing hogs. Doses of 0, 2, 4, 8, and 16 mg of rpPRL/d and 4 mg of recombinant porcine somatotropin (rpST)/d were administered to groups of seven barrows and seven gilts initially weighing 75.

Effect of bovine somatotropin administered to periparturient dairy cows on the incidence of metabolic disease.

Thirty-eight dry, pregnant Jersey cows were assigned to diet and bST treatment in a 2 x 2 factorial design. During the dry period, half of the cows were fed a normal TMR (0.4% Ca; 0.

Nutrition during the dry period and hepatic lipid metabolism of periparturient dairy cows.

From dry-off until 7 d before expected parturition date, 30 Holstein cows were fed a low energy diet (control) to maintain body condition or high energy diets (high fat or isocaloric high grain) to attempt to increase body condition. After parturition, all cows were fed a common lactation diet. Body condition was unchanged for cows fed control or high grain diets, but was decreased for cows fed the high fat diet because DMI was decreased.

The effects of bovine somatotropin (bST) and porcine somatotropin (pST) on growth factor and metabolic variables in horses.

Effects of exogenous pST and bST on metabolic and growth factor variables were examined in three studies with lighthorse mares (455 to 545 kg). In Study 1, eight mares received five s.c.

Effect of supplemental dietary fat or protein on the short-term milk production response to bovine somatotropin.

Effects of supplemental energy or protein on the milk production response to bST administration were examined in two separate trials. In trial 1, 40 cows were used in a 2 x 2 factorial, completely randomized design to determine the effects of bST and fat supplementation. The study consisted of a 7-d pretreatment period and a 42-d treatment period.

Comparative effectiveness of somatotropin and anabolic steroids in feedlot steers.

Crossbred steers (n = 252, BW = 379 +/- 28 kg) were allotted to 42 pens in a 2 x 3 factorial arrangement of treatments: control or steroid implant (STR; estradiol benzoate+progesterone [three lighter blocks reimplanted on d 84] and trenbolone acetate [reimplanted on d 63]), and either 0, 80, or 160 mg/wk of recombinant bovine somatotropin (bST). Steers were adapted to the finishing diet (12% roughage equivalent, 13% CP) before the start of the experiment and fed for 84 or 119 d. Blood samples were taken on d 0, 14, 28, 56, and 84 for plasma urea N (PUN), serum somatotropin (ST), plasma insulin-like growth factor I (IGF-I), and plasma amino acid assay.

Performance, clinical chemistry, and carcass responses of finishing lambs to formulated sometribove (methionyl bovine somatotropin).

Formulated zinc methionyl bST (sometribove, 50, 100, or 150 mg) was administered as a single treatment once every 2 wk or as two equal treatments once/week to evaluate the efficacy of prolonged release delivery of bovine somatotropin (bST) in finishing lambs. Feed conversion during the 6-wk treatment period was improved 9 and 19% in lambs that received treatments once and twice/2 wk, respectively (P < .05), and the responses to differing doses were similar within a dosing frequency (P > .

Effects of recombinant bovine somatotropin implants on serum concentrations of somatotropin, insulin-like growth factor-I and blood urea nitrogen in steers.

Four cross-bred beef steers averaging 346 kg were used in a 4 x 4 Latin square design to determine the effect of prolonged-release recombinant bovine somatotropin (rbGH) implants on serum concentrations of somatotropin (GH), insulin-like growth factor-I (IGF-I) and blood urea nitrogen (BUN). Recombinant bGH implants of 0, 40, 80 or 160 mg were administered subcutaneously in the tailhead during the 4 trial periods. Each steer received each treatment starting at 06:00 on day 0 with 21 days between treatments.

Stimulation of mammogenesis and lactogenesis by recombinant bovine placental lactogen in steroid-primed dairy heifers.

A model of induced lactation was modified to examine the effects of bovine prolactin (bPRL) and bovine placental lactogen (bPL) on mammary growth and differentiation. Thirty-two peripubertal, non-pregnant Holstein heifers were given daily s.c.

Performance, clinical chemistry, and carcass responses of finishing lambs to recombinant bovine somatotropin and bovine placental lactogen.

Bovine placental lactogen (PL) is a partial somatotropin agonist in the cow and decreases urea nitrogen, indicating increased nitrogen retention. In the present study, the somatogenic effects of bovine PL (bPL; 4 and 8 mg/d) were compared with those of bovine somatotropin (bST; 4 and 8 mg/d) in finishing lambs. Measures of comparison included growth performance, carcass composition, and growth-related clinical chemistry traits.

Performance, carcass composition, and blood hormones and metabolites of finishing pigs treated with porcine somatotropin in hot and cold environments.

Two experiments were conducted to assess the ability for recombinant porcine somatotropin (rpST)-treated pigs to perform and cope with the demands of hot and cold environments. In the first experiment, finishing pigs were exposed to either a thermoneutral (TN; 18 to 21 degrees C) or a hot environment (H; 27 to 35 degrees C) for 35 d. In the second experiment, pigs were exposed to a TN or cold environment (C; 5 to 15 degrees C).

Comparison of performance, clinical chemistry, and carcass characteristics of finishing lambs treated with recombinant ovine or bovine somatotropins.

The variation in growth and carcass composition responses of lambs to somatotropin (ST) treatment may depend on the source of ST used as well as on other experimental conditions. In the present experiment, growth, carcass composition, and clinical chemistry responses to recombinantly produced ovine ST (oST) and two bovine ST (N-methionyl-bST[M-bST] and N-alanyl-bST[A-bST] were compared. Lambs weighing 42 kg were assigned to treatment groups of control (no injection) or 4 mg/d of M-bST, A-bST, or oST administered by s.

Effects of decreased availability of glucose for dairy cows.

After a preliminary trial to establish dose responses to phlorizin, five Holstein cows at 6 wk postpartum were used to test the response of cows in negative energy balance to a sudden decrease in availability of glucose caused by phlorizin. Cows were fed equal amounts of feed twice daily to supply 100% of NRC recommendations for protein and 90% of NRC recommendations for NEL and were in negative energy balance throughout the experiment. Phlorizin at 0, 2, and 4 g/d was injected subcutaneously in equal amounts every 6 h for 48 h and caused excretion of 0, 225, and 337 g/d of glucose in urine.

Relationship of mode of porcine somatotropin administration and dietary fat to the growth performance and carcass characteristics of finishing pigs.

Ninety-six pigs were used to investigate the relationship of diet (control vs fat-supplemented with equal energy:protein ratios), porcine somatotropin (pST) administration (non-treated; 2 mg/d, daily injection; and 2 mg/d, 6-wk implant), and sex (barrows and gilts) to performance and carcass characteristics. Diet and pST treatments were initiated at 87 kg of BW and continued for 38 d. Both the fat-supplemented diet (P less than .

Insulin-like growth factors and binding proteins in ruminants and their nutritional regulation.

Insulin-like growth factors (IGF) are important mediators of growth, lactation, reproduction, and health. Considerable information on their role in ruminant animals has been learned in the past several years, but the precise mechanisms of their action are not known. The exact biological response of target cells is undoubtedly determined by the developmental state of the cell and synergism with other growth factors.

Dose-response effects of recombinant bovine somatotropin implants on feedlot performance in steers.

One hundred twenty crossbred beef steers averaging 377 kg were used in a 2 x 4 factorial experiment to determine the dose-response effects of recombinant bovine somatotropin (rbST) implants on growth performance and carcass characteristics. The implant dosages were 0 (sham), 40, 80, or 160 mg/wk administered s.c.

Stimulation of milk yield and feed intake by bovine placental lactogen in the dairy cow.

A 6 x 6 Latin square design was used to test the effects of recombinant bovine placental lactogen on milk yield, milk composition, feed intake, and blood hormone and metabolite levels in nonpregnant lactating cows. The six treatments (5, 10, 20, and 40 mg/d of placental lactogen, water as negative control, and 20 mg/d of bST as positive control) were administered by subcutaneous injection twice daily for 9 d. Blood samples were taken during the last 5 d of the treatment period.

Serum half-life and in-vivo actions of recombinant bovine placental lactogen in the dairy cow.

The clearance rate of recombinant bovine placental lactogen (rbPL) from the blood serum of four lactating dairy cows was measured using a specific radioimmunoassay. Two animals were non-pregnant, while the other two were at approximately 120 days of gestation. The rbPL was administered as an i.

Effects of sometribove on zinc metabolism and tissue mineral concentration in dairy calves.

The metabolism of Zn and tissue mineral concentrations were studied after a single oral 65Zn dose in 10 6-wk-old Holstein calves injected subcutaneously daily with 0 (control) or 10 mg of sometribove (recombinant methionyl bST) for 6 wk. Zinc-65 absorption was not significantly affected by bST; its concentration in the semitendinosus muscle was reduced by 32% in the bST calves, but concentrations in liver, pancreas, spleen, kidney, heart, small intestine, testicle, and rib were not different from controls. Manganese content was reduced by 27% in liver, 60% in kidney, 99% in spleen, 92% in testicles, and 33% in rib.

Metabolic changes in blood and liver of dairy cows during either feed restriction or administration of 1,3-butanediol.

Previous research has shown that a combination of feed restriction and dietary 1,3-butanediol starting at 14 d post-partum resulted in fatty liver and ketosis. Sixteen multiparous Holstein cows were used to determine effects of feed restriction or 1,3-butanediol as separate treatments. Treatments during d 14 to 42 postpartum were 1) control (ad libitum intake), 2) 20% feed restriction, or 3) control plus dietary 1,3-butanediol (5.

Metabolic changes in blood and liver during development and early treatment of experimental fatty liver and ketosis in cows.

Eighteen cows were assigned in equal numbers to three groups: control, ketosis induction by using feed restriction plus dietary 1,3-butanediol to provide ketone bodies, and glucose treatment with 484 g/d of glucose infused intraduodenally starting 7 d after beginning ketosis induction. Ketosis induction, begun at d 15 postpartum, caused ketonemia and gradual development of clinical ketosis by d 40 to 45. None of the cows in the control or glucose-treated groups became ketotic.